Protagonist Therapeutics (PTGX) Protagonist Therapeutics, currently trading around $55.69, is a compelling story in the biotechnology sector. This company is making significant strides in developing innovative peptide therapeutics for various diseases, including a recently announced foray into the highly lucrative obesity market with its PN-477 program. This triple agonist peptide, with both oral and injectable options, holds the promise of being a best-in-class treatment, and while early, it signals a strong commitment to pipeline expansion and addressing major unmet medical needs. With analysts projecting a high price target of $82.00 according to stockanalysis.com, PTGX offers a potential upside of approximately 47.28% from its current price, showcasing its significant growth potential as its clinical programs advance. Don't miss out: View the full Strong Buy portfolio that savvy investors are already acting on. |
